191217-81-9

Basic information

• Product Name: Pramipexole
• Synonyms: Mirapex;(S)-2-Amino-6-(propylamino)-4,5,6,7-tetrahydrobenzothiazol2HClH2Otetrahydrobenzothiazol;Mirapex,Sifrol,Mirapexin;Pramipexole dihydrochloride monohydrate;(6S)-N'-Propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine hydrate dihydrochloride;(S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole dihydrochloride monohydrate;Pramipexole;2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N6-propyl-, dihydrochloride, monohydrate, (6S)-
• CAS NO: 191217-81-9
• Molecular Formula: C10H21Cl2N3OS
• Molecular Weight: 302.26
• EINECS: 1806241-263-5
• Product Categories: Pramipexole;Inhibitors
• Mol File: 191217-81-9.mol
• Article Data: 4

Chemical Properties

• Melting Point: 290 °C(dec.)
• Boiling Point: 378 °C at 760 mmHg
• Flash Point: 182.4 °C
• Appearance: gray white crystalline powder
• Vapor Pressure: 9.93E-11mmHg at 25°C
• Storage Temp.: 2-8°C
• Solubility: Freely soluble in water, soluble in methanol, sparingly soluble or slightly soluble in ethanol (96 per cent), practically insoluble in methylene chloride.
• Merck: 14,7705
• CAS DataBase Reference: Pramipexole(CAS DataBase Reference)
• NIST Chemistry Reference: Pramipexole(191217-81-9)
• EPA Substance Registry System: Pramipexole(191217-81-9)

Safety Data

• WGK Germany: 3
• RTECS: DL3375000
• Hazardous Substances Data: 191217-81-9(Hazardous Substances Data)

Usage

Chemical Properties

White or almost white, crystalline powder.

Uses

Different sources of media describe the Uses of 191217-81-9 differently. You can refer to the following data:
1. These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.
2. Antidepressant; antiparkinsonian; antischizophrenic; dopamine agonist.

Definition

ChEBI: A hydrate that is the monohydrate of the dihydrochloride salt of pramiprexole.

General Description

Pramipexole Dihydrochloride is a non-ergot dopamine agonist widely used for the treatment of early and advanced Parkinson′s disease (PD). It is also used to treat restless legs syndrome.Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.

Clinical Use

Parkinson’s disease Symptomatic treatment of restless legs

Drug interactions

Potentially hazardous interactions with other drugs Avoid concomitant use with antipsychotics.

Metabolism

Pramipexole undergoes <10% metabolism to inactive metabolites. More than 90% of a dose is excreted via renal tubular secretion unchanged into the urine.

InChI:InChI=1/C10H17N3S.2ClH.H2O/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8;;;/h7,12H,2-6H2,1H3,(H2,11,13);2*1H;1H2

Upstream product

• 104632-26-0 pramipexole 
• 943319-02-6 2-amino-6-propylamino-4,5,6,7-tetrahydrobenzothiazole p-toluenesulfonic acid 
• 106006-84-2 (S)?2?amino?6?propionamido?4,5,6,7?tetrahydrobenzothiazole 
• 104632-25-9 pramipexole dihydrochloride 

Relevant articles and documents

Preparation method of high-purity pramipexole dihydrochloride

The invention provides a preparation method of high-purity pramipexole dihydrochloride, which comprises the following steps: (a) by using (S)-2-amino- 6-propionamido 4, 5, 6, 7-tetrahydrobenzothiazoleas a raw material and tetrahydrofuran as a solvent, reacting in the presence of a reducing agent, and adding diluted hydrochloric acid to terminate the reaction after the reaction is completed; (b) adding a sodium hydroxide solution to adjust the pH value, adding an extraction agent for extraction, adding an alcohol reagent, dropwise adding concentrated hydrochloric acid for salifying, cooling for crystallization, filtering and drying to obtain pramipexole dihydrochloride monohydrate; and (c) refining the pramipexole dihydrochloride monohydrate obtained in the step (b) through a ternary system of water, an alcohol reagent and an ester reagent, filtering and drying to obtain a pramipexole dihydrochloride finished product. The novel synthetic method of pramipexole dihydrochloride is simplein reaction steps, high in safety, high in yield, stable in water content and suitable for industrial production, and the purity of pramipexole dihydrochloride reaches 99.95% or above. The pramipexoledihydrochloride has stable water content and is suitable for industrial production.

PROCESSES FOR THE PREPARATION OF PRAMIPEXOLE AND SALTS THEREOF

The invention relates to processes for the preparation of pramipexole or pharmaceutically acceptable salts thereof. More particularly, it relates to a process for the preparation of pramipexole dihydrochloride monohydrate. The invention also relates to a novel compound, 2-bromo-4-aminocyclohexanone and processes for its preparation. The 2- bromo-4-aminocyclohexanone is a useful intermediate in the preparation of pramipexole or salts thereof. The invention further relates to a single step process for the preparation of 2,6-diamino-4,5,6,7-tetrahydrobenzathiazole, an intermediate useful in the preparation of pramipexole or salts thereof.